Ongoing Projects

HOME > R&D Pipeline > Current status > Ongoing Projects

KDDF-201612-16 Lead optimization as drug candidate for pre-clinical study in anaplastic thyroid cancer (ATC)(Oncology, Chemical) [2019-03-18]

PRINT
Ongoing Project
Section Lead
Generation
Lead
Optimization
Preclinical Phase I Phase II Phase III

Development and Market Objectives

Identify final drug candidate suitable for pre-clinical study using KH-NDTC/BH-NDTC(ERRγ inverse agonist) by performing requiring further studies and will set innovative global drug candidate

Unmet Medical Need & Target Patients

Target patients : Anaplastic Thyroid Cancer (ATC)

Unmet Medical Need: Anaplastic thyroid cancer is an orphan and malignant cancer. However, there were no optimal treatments for anaplastic thyroid cancer without surgery.

Status

Comparative studies are ongoing for lead optimization with KH-NDTC/BH-NDTC.

  • In vitro/in vivo efficacy

  • The relation with NIS(sodium/iodide symporter) and thyroid specific genes by novel ERRγ inverse agonists

  • In vitro AMEDT

Intellectual Property

Domestic patent and PCT patent about new substances that show effect on treatment of undifferentiated thyroid cancer is applied and for each international countries, the patent application is being prepared

- 2 patents in Korea (2016) & 2 PCT (2016)

Competitive Advantages

There were no optimal treatments for anaplastic thyroid cancer in associated with diverse clinical unmet needs

The novel ERRγ inverse agonists synergistically increase anti-cancer effect with radioiodine or chemotherapy through recovery of NIS function and increase of radioiodine uptake. It will be possible to expand indications to other type of thyroid cancer and to decrease the side effects of radioiodine and chemotherapy by reduction of its dose.

To be positioned the First-in-class innovation therapeutic agent through novel target mechanism of global new drug development with high efficacy and safety

Contact & Company Overview

Related Project

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code